PARIS, FRANCE,
September 4, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the cooptation of Pascal Touchon as an independent director on its Board of Directors as of October 4, 2023. The appointment of Pascal Touchon follows Paul Sekhri’s decision to step down as a director on the same date due to other professional commitments.
Expert in biotechnology and leader of the pharmaceutical sector, Pascal Touchon is the CEO of Atara Biotherapeutics. He previously held several management positions at Novartis and Servier, and also served on the Board of Directors of various biotechs. With more than 30 years of experience, Pascal Touchon will bring to Ipsen solid expertise in the biotechnology and pharmaceutical fields, which he acquired respectively in the United States and around the world. A graduate of INSEAD, he holds an MBA.
Following this cooptation, the Board of Directors will still consist of 14 directors, including seven women
1
and seven men. The directors include four independent directors and two directors representing employees.
Pascal Touchon will also be a member of the Appointments Committee, the Innovation and Development Committee and the Audit Committee.
This decision will be subject to ratification at the next General Meeting of Shareholders and will be effective for the remainder of Paul Sekhri’s term of office, until the General Meeting of Shareholders in 2026.
On behalf of the Board of Directors, Marc de Garidel, Chairman, would like to thank Paul Sekhri for his contribution and commitment to the Board and other Ipsen committees over the past five years.
END
Ipsen
Ipsen is a mid-sized global biopharmaceutical company focused on the development of innovative medicines in Oncology, Rare Diseases and Neurosciences. With Group sales of 3.0 billion euros for the 2022 financial year, Ipsen sells medicines in more than 100 countries. In addition to its external innovation strategy, Ipsen’s R&D efforts are focused on its differentiated and innovative technology platforms located at the heart of global biotechnology or life science research clusters: Paris-Saclay, France; Oxford, UK; Cambridge, USA; Shanghai, China. Ipsen employs approximately 5,400 people worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a
American Depositary Receipt
(ADR: IPSEY) sponsored level I. Ipsen’s website is ipsen.com.
For more information :
|
contacts
Investors | |
|
Craig Marks Vice President, Investor Relations +44 (0)7584 349 193 |
Nicholas Bogler Senior Manager, Investor Relations +33 6 52 19 98 92 |
Media | |
|
Amy Wolf VP, Head of Corporate Brand Strategy & Communications +41 79 576 07 23 |
Ioana Piscociu Senior Manager Global Media Relations +33 6 69 09 12 96 |
Warning IPSEN
The forward-looking and objective statements contained in this presentation are based on Ipsen’s current management strategy, beliefs and assumptions. These projections and objectives may be affected by known or unknown risks and contingencies that could cause actual results, performance or events to differ materially from those contemplated in this press release. Such risks and contingencies could affect Ipsen’s ability to achieve its financial objectives, which are based on reasonable assumptions as to future macroeconomic conditions based on information available to date. The use of the words “believes”, “intends” and “anticipates” or similar expressions is intended to identify forward-looking statements, including Ipsen’s expectations regarding future events such as submissions and regulatory decisions. In addition, the objectives mentioned in this document are established without taking into account any future external growth operations that could modify all these parameters. These objectives are notably based on data and assumptions considered reasonable by Ipsen. They take into account circumstances or facts likely to occur in the future, and not exclusively historical data. Actual results could differ materially from these objectives given the materialization of certain risks or uncertainties, in particular the fact that a new product which appeared promising during a preparatory phase of development or following tests clinical trials may never be marketed or fail to achieve its commercial objectives, for regulatory or competitive reasons, among other reasons. Ipsen must or may have to face competition from generic products, which could lead to market share losses. In addition, the research and development process includes several stages and, during each stage, there is a significant risk that Ipsen will not be able to achieve its objectives and will be led to abandon its efforts on a product in which it has invested. considerable sums. Also, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed later during clinical trials or that the results of these will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no assurance that a drug will receive necessary approvals or be commercially successful. Actual results could differ materially from those in the forward-looking statements if underlying assumptions prove inaccurate or certain risks or uncertainties materialize. Other risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends towards greater health cost containment; technological advances, new drugs and patents obtained by competitors; issues inherent in the development of new drugs, including obtaining approval; Ipsen’s ability to accurately predict future market conditions; production difficulties or delays; financial instability in the international economy and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other innovative drug protections; and the risk of litigation, including patent litigation or regulatory actions. Ipsen also depends on third parties for the development and marketing of its drugs, which may give rise to substantial royalties; moreover, these partners could act in such a way as to harm Ipsen’s activities and its financial results. Ipsen cannot be certain that its partners will honor their commitments. Ipsen may not be able to take advantage of the agreements entered into. A default by one of its partners could lead to an unforeseen drop in revenue for Ipsen. Such situations could have a negative impact on Ipsen’s business, financial situation or results. Subject to the legal provisions in force, Ipsen makes no commitment to update or revise the forward-looking statements or objectives referred to in this press release in order to reflect changes that would affect the events, situations, assumptions or circumstances on which these statements merge. Ipsen’s business is subject to risk factors which are described in its information documents registered with the Autorité des marchés financiers. The risks and uncertainties presented are not the only ones that Ipsen may face and the reader is invited to read the Group’s 2022 Universal Registration Document available on its website www.ipsen.com.
1
That is 42%, the directors representing the employees not being taken into account in this calculation, in accordance with article L.225-18-1 of the French Commercial Code.
Attachment
Ipsen PR_Pascal Touchon Appointment_04092023